Veracyte Inc
Change company Symbol lookup
Select an option...
VCYT Veracyte Inc
UPST Upstart Holdings Inc
GILT Gilat Satellite Networks Ltd
LAIXY LAIX Inc
SPHD Invesco S&P 500® High Dividend Low Volatility ETF
OXBR Oxbridge Re Holdings Ltd
NVO Novo Nordisk A/S
JNJ Johnson & Johnson
SCHD Schwab U.S. Dividend Equity ETF™
PAYS Paysign Inc
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

Veracyte, Inc. is a genomic diagnostics company. The Company offers customized biomarker testing and analytical services. It offers a complete range of in vitro diagnostic (IVD) and companion diagnostic development services to biopharmaceutical companies and diagnostic companies. It offers tests across various diseases, which include Afirma Genomic Sequencing Classifier for thyroid cancer; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer; Prosigna Breast Cancer Assay for breast cancer; Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer; Envisia Genomic Classifier test for interstitial lung diseases; Decipher Bladder Genomic Classifier test for bladder cancer and Immunoscore Colon Cancer Test for colon cancer. It also offers Immunogram, a spatial molecular analysis and bioinformatics tool that integrates genomic, transcriptomic and proteomic data to help researchers understand the intricacies of the tumor immune microenvironment.

Closing Price
$16.60
Day's Change
-0.04 (-0.24%)
Bid
--
Ask
--
B/A Size
--
Day's High
17.41
Day's Low
16.54
Volume
(Light)
Volume:
853,388

10-day average volume:
1,189,857
853,388

VCYT's position in the Biotechnology industry

Industry PeersVCYTMYGNOPKCDNANVTA

Summary

Company ProfileVeracyte, Inc. is a genomic diagnostics company. The Company offers customized biomarker testing and analytical services. It offers a complete range of in vitro diagnostic (IVD) and companion...
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company primarily provides testing and collaborative development of testing that is designed to assess an individual’s...
Go to MYGN summary
OPKO Health, Inc. is a healthcare company. The Company’s segments include Diagnostics and Pharmaceutical. The Diagnostics segment consists of the clinical laboratory operations of Bio-Reference...
Go to OPK summary
CareDx, Inc. is a precision medicine company. The Company is focused on the discovery, development, and commercialization of clinically differentiated, diagnostic solutions for transplant patients...
Go to CDNA summary
Invitae Corporation is a medical genetics company. The Company is engaged in delivering genetic testing services that support a lifetime of patient care from inherited disease diagnoses, to family...
Go to NVTA summary
52-Week Change

VS. INDUSTRY
-64.44%
-40.17%
-47.21%
-74.44%
-91.42%
Market Cap

VS. INDUSTRY
$1.2B
$1.5B
$1.4B
$867.1M
$567.0M
Beta

VS. INDUSTRY
1.2
1.8
1.8
1.1
1.6
Dividend Yield

VS. INDUSTRY
--
--
--
--
--
P/E (TTM, GAAP)

VS. INDUSTRY
--
--
--
--
--
Data as of

Fundamentals

Total Revenue (TTM)

VS. INDUSTRY
$268.4M
$672.3M
$1.4B
$314.9M
$500.8M
Profit Margin

VS. INDUSTRY
-18.13%
-2.62%
-14.11%
-22.04%
-620.69%
Earnings Growth
(5 year, GAAP)

VS. INDUSTRY
--
--
--
--
--
Revenue Growth (TTM)

VS. INDUSTRY
70.42%
1.51%
-25.34%
24.16%
28.72%
Data as of
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.